However, currently, HT alone may be an option as TTR-specific therapy, such as tafamidis or a silencing agent (in patients with ATTRv-CM), can be prescribed post-transplant if coexisting amyloidosis-related polyneuropathy is present [236]. Here, TTR is linked to amyloidosis.